Eglucent Mix

Wash your hands before injecting. Choose a site for injection. Clean the skin as instructed. Remove outer needle cap. Stabilize the skin by spreading it or pinching up a large area. Insert the needle as instructed. Press the knob. Pull the needle out and apply gentle pressure over the injection site for several seconds. Do not rub the area. Using the outer needle cap, unscrew the needle and dispose of it safely. Use of injection sites should be rotated so that the same site is not used more than approximately once a month.

The insulin device should be rotated in the palms of the hands ten times and inverted 180° ten times immediately before use to resuspend the insulin until it appears uniformly cloudy or milky. If not, repeat the above procedure until contents are mixed. Do not shake vigorously as this may cause frothing which may interfere with the correct measurement of the dose. The device/cartridge should be examined frequently and not be used if clumps of material are present or if solid white particles stick to the bottom or wall of the cartridge, giving a frosted appearance.

Yes, you need to prime your pen. If you do not prime, you may get too much or too little insulin. For priming, turn the dose knob to 2 units. Hold your pen with the needle pointing up. Tap the cartridge holder gently to collect air bubbles at the top. Continue holding your pen with the needle pointing up. Push the dose knob in until it stops and "0" is seen in the dose window. Hold the dose knob in and count to 5 slowly. You should see insulin at the tip of the needle.

Pushing the dose knob of the pen more slowly will make it easier to inject. Your needle may be blocked. Put on a new needle and prime the pen.

Low blood sugar (hypoglycemia) is the most common side effect. This may be associated with listlessness, confusion, palpitations, headache, sweating, and vomiting. Always carry a quick source of sugar such as glucose tablets, hard candy or juice to treat low blood sugar. Use of insulin is contraindicated during the episodes of hypoglycemia. Other possible side effects include severe life-threatening allergic reactions and reactions at the injection site.

If you are experiencing any side effects, please contact your doctor.

Insulin requirements may be increased by medications with hyperglycemic activity (medicines that increase glucose levels) such as corticosteroids, isoniazid, certain lipid-lowering drugs (e.g., niacin), estrogens, oral contraceptives, phenothiazines, and thyroid replacement therapy.

Insulin requirements may be decreased in the presence of drugs that increase insulin sensitivity or have hypoglycemic (glucose lowering) activity, such as oral antidiabetic agents, salicylates, sulfa antibiotics, certain antidepressants (monoamine oxidase inhibitors), angiotensin-converting-enzyme inhibitors, angiotensin II receptor blocking agents, beta-adrenergic blockers, inhibitors of pancreatic function (e.g., octreotide), and alcohol. Beta-adrenergic blockers may mask the symptoms of hypoglycemia in some patients.

Data on a large number of exposed pregnancies do not indicate any adverse effect of insulin lispro (main constituent of Eglucent Mix 25 100IU/ml Suspension for Injection) on pregnancy or on the health of the fetus/newborn. Insulin requirements usually fall during the first trimester and increase during the second and third trimesters. Patients with diabetes should inform their doctor, if they are pregnant or are contemplating the pregnancy. Careful monitoring of glucose control, as well as general health, is essential in pregnant patients with diabetes. Patients with diabetes who are breastfeeding may require adjustments in insulin dose, diet or both.